Bravecto is a veterinary medicine indicated for the treatment and control of flea and tick infestations in dogs. Its active ingredient is fluralaner, a compound from the isoxazoline class, which acts systemically, that is, it acts via the bloodstream after oral administration of the chewable tablet. Main characteristics of Bravecto: Prolonged efficacy: Bravecto provides protection for up to 12 weeks against fleas and ticks, eliminating parasites quickly after exposure to the active ingredient (fleas in up to 8 hours and ticks in up to 12 hours). Method of administration: It is a chewable, tasty tablet, making it easy for dogs to administer and accept. The dose is adjusted according to the animal's weight, and for dogs weighing more than 56 kg, a combination of two tablets can be used. Safety: It can be used on puppies from 8 weeks of age and weighing more than 2 kg, in addition to being safe for pregnant and lactating dogs and dogs with mdr1 gene deficiency. It should be used with caution in dogs with a history of seizures and is contraindicated in cases of hypersensitivity to the product or severe renal/hepatic insufficiency. Elimination of the active ingredient: Fluralaner has a long half-life (approximately 12 days) and is mainly eliminated through feces, with low renal clearance. Additional benefits: In addition to eliminating parasites in the animal, Bravecto helps control the flea population in the environment, contributing to the treatment of flea allergy dermatitis (FAD). Available forms: Chewable tablets for dogs, in different dosages according to weight. Transdermal presentations for dogs and cats, which are alternatives for animals with special needs or difficulties in oral administration. A version called Bravecto 365 offers protection for up to one year with a single dose administered by the veterinarian. In summary, Bravecto is an effective, practical and long-lasting flea and tick repellent, widely used to ensure the health and well-being of dogs, with ease of use and proven high safety.
